Omalizumab and new therapeutic targets in chronic spontaneous urticaria

Abstract Chronic spontaneous urticaria (CSU) is a common and distressing skin disease characterized by itchy wheals, angioedema, or both. There is currently no cure for CSU and symptomatic treatment is often insufficient. Omalizumab, a humanized anti-immunoglobulin (Ig) E monoclonal antibody, remains the only biological drug licensed for CSU, almost a decade after its approval. However, growing knowledge of the pathophysiological mechanisms of this disease has led to recent advances in its treatment, with several drugs in investigation both in pre-clinical and clinical settings. These include biologicals, such as dupilumab (anti-IL-4Rα), secukinumab (anti-IL-17), tezepelumab (anti-TSLP), ligelizumab (anti-IgE), lirentelumab (anti-Siglet 8), and barzovolimab (anti-cKIT), as well as “small molecules,” such as Bruton tyrosine kinase (BTK) inhibitors (remibrutinib) and a Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist. Here, we review the current and future therapeutic options for CSU, based on what is known about the pathogenesis of the disease.

Bibliographic Details

Main Authors:	Pereira,Ana S., Xará,Joana, Flor,Duarte, Gonçalo,Margarida
Format:	Digital revista
Language:	English
Published:	Permanyer Publications 2024
Online Access:	http://scielo.pt/scielo.php?script=sci_arttext&pid=S2795-50012024000100011
Tags:	Add Tag No Tags, Be the first to tag this record!